Hypoxia-targeted drug delivery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sharma, Amit | - |
dc.contributor.author | Arambula, Jonathan F. | - |
dc.contributor.author | Koo, Seyoung | - |
dc.contributor.author | Kumar, Rajesh | - |
dc.contributor.author | Singh, Hardev | - |
dc.contributor.author | Sessler, Jonathan L. | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-01T19:14:01Z | - |
dc.date.available | 2021-09-01T19:14:01Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-02-04 | - |
dc.identifier.issn | 0306-0012 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/67675 | - |
dc.description.abstract | Hypoxia is a state of low oxygen tension found in numerous solid tumours. It is typically associated with abnormal vasculature, which results in a reduced supply of oxygen and nutrients, as well as impaired delivery of drugs. The hypoxic nature of tumours often leads to the development of localized heterogeneous environments characterized by variable oxygen concentrations, relatively low pH, and increased levels of reactive oxygen species (ROS). The hypoxic heterogeneity promotes tumour invasiveness, metastasis, angiogenesis, and an increase in multidrug-resistant proteins. These factors decrease the therapeutic efficacy of anticancer drugs and can provide a barrier to advancing drug leads beyond the early stages of preclinical development. This review highlights various hypoxia-targeted and activated design strategies for the formulation of drugs or prodrugs and their mechanism of action for tumour diagnosis and treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ROYAL SOC CHEMISTRY | - |
dc.subject | SELECTIVE ANTITUMOR AGENTS | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | HUMAN TUMOR-CELLS | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | DT-DIAPHORASE ACTIVITY | - |
dc.subject | MONO-N-OXIDES | - |
dc.subject | O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AGT | - |
dc.subject | NADPH CYTOCHROME-P450 REDUCTASE | - |
dc.subject | BIOREDUCTIVE PRODRUG PR-104A | - |
dc.subject | MUSTARD QUATERNARY-SALTS | - |
dc.title | Hypoxia-targeted drug delivery | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1039/c8cs00304a | - |
dc.identifier.scopusid | 2-s2.0-85060630431 | - |
dc.identifier.wosid | 000457793900008 | - |
dc.identifier.bibliographicCitation | CHEMICAL SOCIETY REVIEWS, v.48, no.3, pp.771 - 813 | - |
dc.relation.isPartOf | CHEMICAL SOCIETY REVIEWS | - |
dc.citation.title | CHEMICAL SOCIETY REVIEWS | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 771 | - |
dc.citation.endPage | 813 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | SELECTIVE ANTITUMOR AGENTS | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | HUMAN TUMOR-CELLS | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | DT-DIAPHORASE ACTIVITY | - |
dc.subject.keywordPlus | MONO-N-OXIDES | - |
dc.subject.keywordPlus | O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AGT | - |
dc.subject.keywordPlus | NADPH CYTOCHROME-P450 REDUCTASE | - |
dc.subject.keywordPlus | BIOREDUCTIVE PRODRUG PR-104A | - |
dc.subject.keywordPlus | MUSTARD QUATERNARY-SALTS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.